Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
36.70
+1.71 (4.89%)
At close: Jun 26, 2026, 4:00 PM EDT
37.32
+0.62 (1.69%)
After-hours: Jun 26, 2026, 7:11 PM EDT
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $10.73M in the quarter ending March 31, 2026, with 2,873.41% growth. This brings the company's revenue in the last twelve months to $1.17M, up 194.24% year-over-year. In the year 2025, Crinetics Pharmaceuticals had annual revenue of $7.70M with 640.71% growth.
Revenue (ttm)
$1.17M
Revenue Growth
+194.24%
P/S Ratio
214.16
Revenue / Employee
$30,419
Employees
594
Market Cap
3.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.70M | 6.66M | 640.71% |
| Dec 31, 2024 | 1.04M | -2.97M | -74.11% |
| Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
| Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
| Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
| Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
| Dec 31, 2019 | 1.19M | -1.24M | -50.86% |
| Dec 31, 2018 | 2.43M | 383.00K | 18.73% |
| Dec 31, 2017 | 2.05M | 1.46M | 247.20% |
| Dec 31, 2016 | 589.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.10B |
| Telix Pharmaceuticals | 803.79M |
| Catalyst Pharmaceuticals | 596.96M |
| Arcus Biosciences | 236.00M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Relay Therapeutics | 10.68M |
CRNX News
- 8 days ago - Crinetics Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 12 days ago - Crinetics presents full results from Phase 2 trial of atumelnant - TheFly
- 12 days ago - Crinetics presents long-term data from program evaluating Palsonify - TheFly
- 12 days ago - Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control - GlobeNewsWire
- 15 days ago - Leerink sees favorable readthrough to Crinetics after Camurus’ Oclaiz CRL - TheFly
- 24 days ago - Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities - GlobeNewsWire
- 24 days ago - Crinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - GlobeNewsWire
- 5 weeks ago - Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 - GlobeNewsWire